This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rogatko, A. Articles by Hudes, G. R. Search for Related Content PubMed PubMed Citation Articles by Rogatko, A. Articles by Hudes, G. R.

Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials

Departments of ¹ Biostatistics and ² Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

ABSTRACT

Purpose: The purpose of this study was to identify patient characteristics that may be risk factors or markers of susceptibility to adverse treatment effects in cancer Phase I and II clinical trials.

Patients and Methods: A total of 459 patients enrolled in 23 therapeutic Phase I and II studies at the Fox Chase Cancer Center were included in the analysis. Patient-specific characteristics, medical and treatment history, doses of experimental agents, and graded toxicities were extracted from case report forms. We developed a novel summary measure, the toxicity index (TI), to better discriminate patients on the basis of their overall toxicity experiences. Mixed model ANOVA was used to model TI on the basis of data from all trials using a specific agent. Generalized estimating equations in the context of binary logistic regression were used to model dose-limiting toxicity.

Results: Seventeen pretreatment factors, including performance status, alkaline phosphatase, total bilirubin, serum creatinine, and tobacco use, emerged as significant predictors of toxicity as defined by dose-limiting toxicity or TI. Unexpectedly, dose was not always a predictor of toxicity. Even for values within the normal range, the TI identified serum bilirubin and alkaline phosphatase as predictors of toxicity after treatment with docetaxel and alkaline phosphatase as a predictor for toxicity after treatment with irinotecan.

Conclusions: Independent of dose, certain pretreatment characteristics, including measures of organ function that are in the normal range, were found to be predictors of treatment toxicity. Because of its sensitivity to differences in overall toxicity, the TI should prove to be a useful tool for identifying predictors of chemotherapy-related toxicity.

This article has been cited by other articles:

				W. Demark-Wahnefried, S. L George, B. R Switzer, D. C Snyder, J. F Madden, T. J Polascik, M. T Ruffin IV, and R. T Vollmer Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer Clinical Trials, June 1, 2008; 5(3): 262 - 272. [Abstract] [PDF]

				G. R. Pond, L. L. Siu, M. Moore, A. Oza, H. W. Hirte, E. Winquist, G. Goss, G. Hudes, and C. A. Townsley Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents J. Clin. Oncol., March 10, 2008; 26(8): 1324 - 1330. [Abstract] [Full Text] [PDF]

				P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769. [Abstract] [Full Text] [PDF]

				E. L. Trimble and M. C. Christian Cancer treatment and the older patient. Clin. Cancer Res., April 1, 2006; 12(7): 1956 - 1957. [Full Text] [PDF]

				C. A. Townsley, G. R. Pond, A. M. Oza, H. W. Hirte, E. Winquist, G. Goss, P. Degendorfer, M. J. Moore, and L. L. Siu Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin. Cancer Res., April 1, 2006; 12(7): 2141 - 2149. [Abstract] [Full Text] [PDF]

				A. Rogatko, J. S. Babb, M. Tighiouart, F. R. Khuri, and G. Hudes New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I Clin. Cancer Res., August 1, 2005; 11(15): 5342 - 5346. [Abstract] [Full Text] [PDF]

				C. Townsley, G. R. Pond, B. Peloza, J. Kok, K. Naidoo, D. Dale, C. Herbert, E. Holowaty, S. Straus, and L. L. Siu Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada J. Clin. Oncol., June 1, 2005; 23(16): 3802 - 3810. [Abstract] [Full Text] [PDF]